Medicus Pharma: Targeting Urinary Retention with a Novel Non-Invasive Therapy
Medicus Pharma is introducing a groundbreaking therapy to prevent relapse in men suffering from acute urinary retention due to enlarged prostate.
Advancing prostate health with innovation backed by proven biotech pioneers
Every year, nearly 1 million men in the U.S. face the sudden and painful onset of acute urinary retention (AUR)—a medical emergency that often leads to repeat ER visits. Medicus Pharma, known for developing the revolutionary skin cancer patch, is now addressing this urgent need with a non-invasive therapy designed to prevent relapse.
Targeting a $2 billion market, Medicus Pharma’s solution could change how prostate-related emergencies are managed, offering relief and reducing the likelihood of recurrence. With a legacy of biotech innovation and a clear clinical focus, Medicus is advancing a therapy that meets an immediate and recurring need for millions.
To learn more about Medicus Pharma (NASDAQ: MDCX), watch their video HERE
Published by BTV - The Agency
Discover Investment Opportunities with BTV. Delivering engaging content to Investors for 25+ years.
.jpg)
You might also like
Critical Elements Lithium Poised to Support Growing Demand Beyond EVs
Critical Elements Lithium is ready to fuel tomorrow’s energy by advancing its Rose Lithium-Tantalum Project in Quebec. The company’s focus is on producing high-purity spodumene concentrate to supply the flourishing electric vehicle and energy storage systems industries.
Critical Elements Lithium: Is Quebec ready to deliver new North American supply?
Global lithium demand is expected to rise from roughly 1.2 million tonnes in 2025 to about 3 million tonnes by 2030, driven largely by electric vehicles and energy storage for ravenous data centres and artificial intelligence. Management believes supply will struggle to keep pace, creating room for new producers with near-term projects.
Harvest HPYB ETF Income From Canadian Banks
Harvest Premium Yield Canadian Bank ETF (HPYB) is built to generate higher income from Canadian bank stocks by combining bank exposure with an active options strategy that sells calls and puts, producing more tax-efficient cash flow than dividends alone.